[{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Accelerates Its Pipeline Clinical Development in New Indications: Cardiovascular and Hepatic Steatosis Risk Reduction","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Valbiotis"},{"orgOrder":0,"company":"MyoKardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology\u2019s Virtual Heart Failure Association Discoveries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"MyoKardia"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I\/II Study in Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Intra-Cellular Therapies"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Doses Patients in Phase 1\/2 Trial Evaluating Novel Gene Therapy XC001 in Refractory Angina","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"XyloCor Therapeutics"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Valbiotis"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","amount":"$41.9 million","upfrontCash":"Undisclosed","newsHeadline":"XyloCor Therapeutics Completes Oversubscribed $41.9 Million Series A Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"XyloCor Therapeutics"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Commences Phase 2 Component of Phase 1\/2 EXACT Study of XC001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"XyloCor Therapeutics"},{"orgOrder":0,"company":"Baker Institute","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.1 million","newsHeadline":"Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Baker Institute"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Presents New Clinical Data on ARO-APOC3 at AHA 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"BioGenCell","sponsor":"Marius Nacht","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"BioGenCell, Developer of A Unique Platform for Treating Microvascular Disease, Has Completed a $16 Million Seed Round Led by Private Investor Marius Nacht","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"BioGenCell"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1\/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"XyloCor Therapeutics"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"XyloCor Therapeutics"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Inozyme Pharma"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"XyloCor Therapeutics"},{"orgOrder":0,"company":"Heartseed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heartseed and Novo Nordisk Announce First Patient Dosed in Clinical Study With HS-001 A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Heartseed"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1\/2 Trials of INZ-701","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Inozyme Pharma"},{"orgOrder":0,"company":"Heartseed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Heartseed and Novo Nordisk Announce First Patient Dosed in Clinical Study With HS-001 \u2013 A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Heartseed"},{"orgOrder":0,"company":"Repairon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1\/2 Trial in Advanced Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Repairon"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Repairon's lead therapeutic candidate BioVAT-HF, an engineered heart muscle (EHM), is being evaluated in a Phase 1/2 clinical trial as biological ventricular assist tissue in terminal heart failure.
HS-001 consists allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. It improves the retention rate and viability of the cell transplant compared to single cell suspensions. It is being developed for restore heart function in advanced heart failure.
INZ-701 is a soluble protein which circulates throughout the body and cleave extracellular ATP into PPi and AMP, a precursor of adenosine. It is being developed for the treatment of ENPP1 and ABCC6 deficiency
HS-001 is an investigational cell therapy consisting of clusters of purified heart muscle cells (cardiomyocyte spheroids) derived from induced pluripotent stem cells (iPSCs) that are designed to restore heart muscle and function in patients with advanced heart failure.
XC001 is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow. By restoring blood flow, it may decrease chest pain associated with refractory angina.
Inozyme Pharma is developing INZ-701, a first-in-class enzyme therapy, to address pathologic mineralization and intimal proliferation which drive morbidity and mortality in these severe diseases. INZ-701 is being developed for the treatment of ENPP1 and ABCC6 Deficiency.
XC001 (encoberminogene rezmadenovec) is a locally administered, single-dose gene therapy currently in development as a novel approach to treating patients with refractory angina who have no other medical and surgical options.
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study.
Financing will support BioGenCell's innovative, accessible and painless medical platform focuses on BGC101 and pipeline. The product BGC101, treats severe limb-threatening ischemia (CLI) typically found in patients with diabetes and heavy smokers.
Four genetically confirmed FCS patients received 50 mg ARO-APOC3 and 26 multifactorial chylomicronemia patients received 10, 25, 50, or 100 mg ARO-APOC3 on days 1 and 29. Since similar responses were observed among MCM pts, results were pooled across dose levels.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
